| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.38B | -9.6% |
| Gross profit | ¥0.07B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.02B | -14.7% |
| Gross margin | 19.5% | Net margin 4.2% |
| Revenue Q/Q | +1.5% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.31B | 80.5% |
| R&D | ¥0.01B | 2.8% |
| SG&A | ¥0.03B | 8.2% |
| Tax & other | ¥0.00B | 0.3% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
汉宇集团 ・ 博济医药 ・ 科隆股份 ・ 九强生物 ・ 凯发电气 ・ 道氏技术 ・ 正业科技 ・ 金盾股份 ・ 迦南科技 ・ 中光防雷 ・ 伊之密 ・ 苏试试验
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies